A Phase 3 interventional study of 13-valent Pneumococcal Conjugate Vaccine in Vaccines, Pneumococcal Conjugate Vaccine, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 16 sites in South Africa. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-04-19.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a follow-up study to the core study NCT00269672 (6115A1-500). This study will further evaluate the safety, tolerability, and immunogenicity of 13-valent pneumococcal conjugate vaccine (13vPnC) when administered to subjects who have already received one dose of 13vPnC, and one dose of 23-valent pneumococcal polysaccharide vaccine (23vPS) one year later. This study will determine if a subsequent dose of 13vPnC one year later results in similar or greater immune response (body's ability to protect against disease) than that measured after the initial dose of 13vPnC.
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
First submitted before Wyeth became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
No history of severe adverse reaction associated with a vaccine
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 dose 13vPnC
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC (Vaccination 1)
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Time frame: Month 1 / Year 0 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)
Pneumococcal OPA Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC / 23vPS (Vaccination 2)
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Time frame: Month 1 / Year 1 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)
Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC (Vaccination 1)
Pneumococcal IgG GMCs measured as micrograms per milliliter (mcg/mL) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMCs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Time frame: Month 1 / Year 0 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)
Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After 13vPnC / 23vPS / 13vPnC (Vaccination 3) Versus 1 Month After 13vPnC / 23vPS (Vaccination 2)
Pneumococcal IgG GMCs measured as micrograms per milliliter (mcg/mL) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMCs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
Time frame: Month 1 / Year 1 (Core study/NCT00269672), Month 1 / Year 2 (Follow-up study/NCT00500357)
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination 13vPnC / 23vPS / 13vPnC (Vaccination 3)
Local reactions reported using electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\> 10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move shoulder).
Time frame: Days 1 through 14 / Year 2 (Follow-up study/NCT00500357)
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination 13vPnC / 23vPS / 13vPnC (Vaccination 3)
Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New muscle pain, Aggravated muscle pain, New joint pain, and Aggravated joint pain.
Time frame: Days 1 through 14 / Year 2 (Follow-up study/NCT00500357)
915 participants were enrolled in core study NCT00269672 (6115A1-500); 914 participants received 13-valent pneumococcal conjugate vaccine plus or minus aluminum phosphate (13vPnC+AlPO4 or 13vPnC-AlPO4) or 23-valent pneumococcal polysaccharide vaccine (23vPS) in Year 0 (Vaccination 1 \[Vax 1\]) followed by 13vPnC+AlPO4 or 23vPS in Year 1 (Vax 2).
| Milestone | 13vPnC (Vax 3 Follow-up / NCT00500357) |
|---|---|
| Started | 105 |
| Received 13vpnc (vax 3) | 105 |
| Evaluable immunogenicity population | 98 |
| Completed | 104 |
| Not completed | 1 |
| Withdrew: Death | 1 |
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
| geometric mean titer | 13vPnC (Vax 1 Core Study/NCT00269672) | 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) |
|---|---|---|
| Serotype 1 | 198 (133.7 to 293.0) | 78 (55.4 to 108.8) |
| Serotype 3 | 126 (94.2 to 167.8) | 104 (81.5 to 132.5) |
| Serotype 4 | 2210 (1603.5 to 3045.2) | 1254 (926.6 to 1695.7) |
| Serotype 5 | 413 (278.0 to 614.9) | 170 (119.7 to 241.3) |
| Serotype 6A | 4931 (3391.0 to 7170.8) | 3158 (2369.3 to 4209.7) |
| Serotype 6B | 3251 (2105.0 to 5019.6) | 2440 (1753.2 to 3395.1) |
| Serotype 7F | 869 (540.3 to 1398.0) | 353 (221.7 to 561.0) |
| Serotype 9V | 977 (588.6 to 1620.4) | 247 (142.9 to 426.8) |
| Serotype 14 | 982 (676.0 to 1425.8) | 550 (392.5 to 769.8) |
| Serotype 18C | 2860 (1899.9 to 4304.6) | 1457 (1057.8 to 2008.1) |
| Serotype 19A | 1141 (832.4 to 1564.3) | 431 (340.3 to 546.1) |
| Serotype 19F | 1014 (654.4 to 1572.6) | 494 (341.4 to 715.5) |
| Serotype 23F | 523 (315.4 to 867.7) | 661 (443.6 to 985.8) |
Local reactions reported using electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\> 10.0 cm). Pain scaled as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move shoulder).
| percentage of participants | 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up/NCT00500357) |
|---|---|
| Redness: Any (n=79) | 7.6 |
| Redness: Mild (n=79) | 6.3 |
| Redness: Moderate (n=78) | 3.8 |
| Redness: Severe (n=78) | 0.0 |
| Swelling: Any (n=83) | 16.9 |
| Swelling: Mild (n=81) | 12.3 |
| Swelling: Moderate (n=81) | 8.6 |
| Swelling: Severe (n=78) | 0.0 |
| Pain: Any (n=89) | 40.4 |
| Pain: Mild (n=88) | 34.1 |
| Pain: Moderate (n=83) | 15.7 |
| Pain: Severe (n=78) | 0.0 |
| Limitation of arm movement: Any (n=80) | 11.3 |
| Limitation of arm movement: Mild (n=80) | 8.8 |
| Limitation of arm movement: Moderate (n=78) | 2.6 |
| Limitation of arm movement: Severe (n=79) | 1.3 |
Systemic events reported using electronic diary. Fever scaled as Any (≥38 degrees Celsius \[C\]); Mild (≥38 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 but ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New muscle pain, Aggravated muscle pain, New joint pain, and Aggravated joint pain.
| percentage of participants | 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up/NCT00500357) |
|---|---|
| Fever: Any ≥38 degrees C (n=81) | 7.4 |
| Fever: Mild ≥38 but <38.5 degrees C (n=80) | 3.8 |
| Fever: Moderate ≥38.5 but <39 degrees C (n=78) | 2.6 |
| Fever: Severe ≥39 but ≤40 degrees C (n=80) | 2.5 |
| Potentially life-threatening >40 degrees C (n=79) | 1.3 |
| Fatigue (n=83) | 27.7 |
| Headache (n=81) | 19.8 |
| Chills (n=79) | 8.9 |
| Rash (n=78) | 2.6 |
| Vomiting (n=79) | 1.3 |
| Decreased appetite (n=82) | 18.3 |
| New muscle pain (n=84) | 21.4 |
| Aggravated muscle pain (n=80) | 12.5 |
| New joint pain (n=78) | 7.7 |
| Aggravated joint pain (n=79) | 6.3 |
Antibody geometric mean titers as measured by opsonophagocytic activity (OPA) assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMTs are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
| geometric mean titer | 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) | 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) |
|---|---|---|
| Serotype 1 | 184 (136.2 to 249.2) | 81 (58.3 to 112.5) |
| Serotype 3 | 131 (102.2 to 168.9) | 104 (81.5 to 132.5) |
| Serotype 4 | 1457 (1092.8 to 1942.2) | 1406 (1098.1 to 1799.8) |
| Serotype 5 | 326 (228.4 to 464.0) | 219 (153.6 to 312.8) |
| Serotype 6A | 1732 (1163.1 to 2580.0) | 3443 (2678.7 to 4425.1) |
| Serotype 6B | 1862 (1333.5 to 2600.7) | 2505 (1798.8 to 3488.1) |
| Serotype 7F | 1292 (925.2 to 1803.5) | 351 (224.5 to 550.1) |
| Serotype 9V | 624 (371.0 to 1051.1) | 267 (153.9 to 463.0) |
| Serotype 14 | 808 (599.4 to 1089.7) | 557 (399.0 to 778.9) |
| Serotype 18C | 1753 (1214.9 to 2528.5) | 1452 (1049.6 to 2009.0) |
| Serotype 19A | 756 (581.2 to 983.9) | 511 (408.5 to 639.1) |
| Serotype 19F | 901 (689.1 to 1177.3) | 527 (369.1 to 752.7) |
| Serotype 23F | 484 (323.7 to 723.6) | 731 (499.0 to 1071.9) |
Pneumococcal IgG GMCs measured as micrograms per milliliter (mcg/mL) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMCs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
| geometric mean concentration (mcg/mL) | 13vPnC (Vax 1 Core Study/NCT00269672) | 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) |
|---|---|---|
| Serotype 1 | 7.67 (5.48 to 10.72) | 4.99 (4.06 to 6.14) |
| Serotype 3 | 2.60 (2.04 to 3.33) | 1.35 (1.12 to 1.62) |
| Serotype 4 | 4.68 (3.40 to 6.43) | 2.96 (2.30 to 3.81) |
| Serotype 5 | 19.51 (13.92 to 27.36) | 6.33 (5.08 to 7.90) |
| Serotype 6A | 9.12 (6.70 to 12.42) | 8.22 (6.30 to 10.72) |
| Serotype 6B | 13.03 (9.11 to 18.62) | 10.32 (8.10 to 13.14) |
| Serotype 7F | 6.93 (5.45 to 8.81) | 5.02 (4.23 to 5.95) |
| Serotype 9V | 11.56 (8.68 to 15.40) | 5.77 (4.70 to 7.09) |
| Serotype 14 | 17.51 (12.70 to 24.13) | 13.34 (10.67 to 16.69) |
| Serotype 18C | 20.59 (15.35 to 27.62) | 7.82 (6.39 to 9.56) |
| Serotype 19A | 29.52 (22.14 to 39.36) | 17.80 (14.67 to 21.60) |
| Serotype 19F | 13.39 (9.47 to 18.92) | 8.55 (6.60 to 11.07) |
| Serotype 23F | 10.16 (7.06 to 14.64) | 7.73 (5.77 to 10.36) |
Pneumococcal IgG GMCs measured as micrograms per milliliter (mcg/mL) for the 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). Confidence intervals (CI) for the GMCs are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.
| geometric mean concentration (mcg/mL) | 13vPnC / 23vPS (Vax 2 Core Study/NCT00269672) | 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study/NCT00500357) |
|---|---|---|
| Serotype 1 | 7.29 (5.96 to 8.93) | 4.99 (4.06 to 6.14) |
| Serotype 3 | 2.46 (2.01 to 3.01) | 1.36 (1.13 to 1.64) |
| Serotype 4 | 3.93 (3.03 to 5.11) | 2.96 (2.30 to 3.81) |
| Serotype 5 | 9.29 (7.37 to 11.71) | 6.33 (5.08 to 7.90) |
| Serotype 6A | 5.51 (4.25 to 7.15) | 8.22 (6.30 to 10.72) |
| Serotype 6B | 9.67 (7.47 to 12.53) | 10.32 (8.10 to 13.14) |
| Serotype 7F | 7.41 (6.07 to 9.04) | 5.02 (4.23 to 5.95) |
| Serotype 9V | 9.60 (7.68 to 12.00) | 5.77 (4.70 to 7.09) |
| Serotype 14 | 22.67 (17.89 to 28.72) | 13.34 (10.67 to 16.69) |
| Serotype 18C | 11.66 (9.66 to 14.07) | 7.82 (6.39 to 9.56) |
| Serotype 19A | 22.78 (18.47 to 28.11) | 17.80 (14.67 to 21.60) |
| Serotype 19F | 15.82 (11.97 to 20.91) | 8.55 (6.60 to 11.07) |
| Serotype 23F | 7.27 (5.52 to 9.57) | 7.73 (5.77 to 10.36) |
Collected over Baseline / Day 1 up to 43 days postvaccination. Local Reactions and Systemic Events assessed within 14 days of vaccination.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study) | — | 2/105 (1.9%) | 46/105 (43.8%) |
| 13vPnC+AlPO4 (After Vax 1 Core Study) | — | 2/308 (0.6%) | 70/308 (22.7%) |
| 13vPnC-AlPO4 (After Vax 1 Core Study) | — | 4/304 (1.3%) | 58/304 (19.1%) |
| 23vPS (After Vax 1 Core Study) | — | 1/302 (0.3%) | 80/302 (26.5%) |
| 13vPnC+AlPO4/13vPnC+AlPO4 (After Vax 2 Core Study) | — | 3/139 (2.2%) | 26/139 (18.7%) |
| 13vPnC+AlPO4/23vPS (After Vax 2 Core Study) | — | 1/128 (0.8%) | 35/128 (27.3%) |
| 13vPnC-AlPO4/23vPS (After Vax 2 Core Study) | — | 1/273 (0.4%) | 76/273 (27.8%) |
| Event | 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study) | 13vPnC+AlPO4 (After Vax 1 Core Study) | 13vPnC-AlPO4 (After Vax 1 Core Study) | 23vPS (After Vax 1 Core Study) | 13vPnC+AlPO4/13vPnC+AlPO4 (After Vax 2 Core Study) | 13vPnC+AlPO4/23vPS (After Vax 2 Core Study) | 13vPnC-AlPO4/23vPS (After Vax 2 Core Study) |
|---|---|---|---|---|---|---|---|
| Cardio-respiratory arrestCardiac disorders | 1/105 | — | — | — | — | — | — |
| Hip fractureInjury, poisoning and procedural complications | 1/105 | — | — | — | — | — | — |
| ArthralgiaMusculoskeletal and connective tissue disorders | — | 0/308 | 0/304 | 0/302 | 0/139 | 1/128 | 0/273 |
| PhimosisCongenital, familial and genetic disorders | — | 0/308 | 0/304 | 0/302 | 1/139 | 0/128 | 0/273 |
| Intervertebral disc disorderMusculoskeletal and connective tissue disorders | — | 0/308 | 0/304 | 0/302 | 1/139 | 0/128 | 0/273 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | — | 0/308 | 0/304 | 0/302 | 1/139 | 0/128 | 0/273 |
| HydrocephalusNervous system disorders | — | 0/308 | 0/304 | 0/302 | 1/139 | 0/128 | 0/273 |
| Myocardial infarctionCardiac disorders | — | 0/308 | 1/304 | 0/302 | 0/139 | 0/128 | 1/273 |
| ExostosisMusculoskeletal and connective tissue disorders | — | 0/308 | 0/304 | 1/302 | 0/139 | 0/128 | 0/273 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | — | 0/308 | 0/304 | 1/302 | 0/139 | 0/128 | 0/273 |
| Event | 13vPnC / 23vPS / 13vPnC (Vax 3 Follow-up Study) | 13vPnC+AlPO4 (After Vax 1 Core Study) | 13vPnC-AlPO4 (After Vax 1 Core Study) | 23vPS (After Vax 1 Core Study) | 13vPnC+AlPO4/13vPnC+AlPO4 (After Vax 2 Core Study) | 13vPnC+AlPO4/23vPS (After Vax 2 Core Study) | 13vPnC-AlPO4/23vPS (After Vax 2 Core Study) |
|---|---|---|---|---|---|---|---|
| Pain (any)Skin and subcutaneous tissue disorders | 36/89 | — | — | — | — | — | — |
| Pain (mild)Skin and subcutaneous tissue disorders | 30/88 | — | — | — | — | — | — |
| FatigueGeneral disorders | 23/83 | — | — | — | — | — | — |
| New muscle painGeneral disorders | 18/84 | — | — | — | — | — | — |
| HeadacheGeneral disorders | 16/81 | — | — | — | — | — | — |
| Decreased appetitieGeneral disorders | 15/82 | — | — | — | — | — | — |
| Swelling (any)Skin and subcutaneous tissue disorders | 14/83 | — | — | — | — | — | — |
| Pain (moderate)Skin and subcutaneous tissue disorders | 13/83 | — | — | — | — | — | — |
| Aggravated muscle painGeneral disorders | 10/80 | — | — | — | — | — | — |
| Swelling (mild)Skin and subcutaneous tissue disorders | 10/81 | — | — | — | — | — | — |
| Age Continuous(years) | 13vPnC (Vax 3 Follow-up / NCT00500357) |
|---|---|
| Mean | 72.8 ± 4.9 |
| Sex: Female, Male(Participants) | 13vPnC (Vax 3 Follow-up / NCT00500357) |
|---|---|
| Female | 56 |
| Male | 49 |
The record gives a start of Nov 2007, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 1 year 1 month after primary completion. A results delay was requested in Jan 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine
Wyeth is now a wholly owned subsidiary of Pfizer →